التكنولوجيا وأخبارها بوابة الإمارات لتكنولوجيا المعلومات والإتصالات
LG Chem Life Sciences and TransThera Biosciences Announce License Agreement for Potential Treatment of
NASH and Other Chronic Inflammatory Conditions
-( LG Chem Life Sciences (“LG Chem”), a division of LG
Chem, and TransThera Biosciences Co. Ltd. (“TransThera”),
a clinical-stage biotechnology company based in Nanjing,
China, announced today that LG Chem has entered an
exclusive license agreement with TransThera, for the
development and commercialization of TransThera’s TT-
01025, a highly selective oral small molecule inhibitor of
Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion
Protein-1 (SSAO/VAP-1) that has shown promising efficacy
in pre-clinical investigation in non-alcoholic steatohepatitis
(NASH). TT-01025 is expected to enter Phase I trial in early
2021 in the US.
This press release features multimedia. View the full
release here:
https://www.businesswire.com/news/home/2020081700
5331/en/
NASH is a chronic and progressive liver disease
characterized by fat accumulation and inflammation in the
liver, which can lead to fibrosis and impaired liver function.
The disease can be silent for a long period of time, but once
it accelerates, severe damage and liver cirrhosis can occur,
which can significantly impact liver function or can even
result in liver failure or liver cancer. There are as yet no
globally approved drugs for the indication. The inhibition of
SSAO/VAP-1 blocks oxidative conversion and leucocyte
transmigration during inflammation processes and exhibits
therapeutic potential across a range of chronic
inflammatory conditions, including NASH.
Under the terms of the agreement, LG Chem will obtain
exclusive worldwide rights, except Greater China region
and Japan, to develop and commercialize TT-01025.
TransThera will receive upfront payment as well as
development and sales milestone payments, totaling up to
$350M, plus tiered royalties on the annual net sales. LG
Chem will be responsible for the further development,
manufacturing and commercialization of TT-01025.
“Leveraging TransThera’s expertise in drug discovery and
LG Chem Life Science’s capability in drug development, we
are excited to expand our portfolio in NASH and other
metabolic disorders,” said Dr. Jeewoong Son, President of
LG Chem Life Sciences. “TT-01025 has a mechanism of
action potentially synergistic with those in our own
pipeline, making a perfect fit for our strategy to tackle the
complex pathophysiology of NASH.”
Dr. Frank Wu, Chairman and CEO of TransThera,
commented, “Open innovation is an important part of
TransThera’s R&D strategy. We are very excited to
collaborate with LG Chem, with its strong and broad
expertise and capabilities, to expedite the global
development of TT-01025. TT-01025 is a novel, highly
differentiated VAP-1 inhibitor, with attributes of minimum
CNS exposure and high selectivity, rendering its low risk of
drug interactions. We look forward to working with LG
Chem to deliver a potential innovative drug for the
treatment of NASH patients.”
